Elanco is proud to introduce HepafleX™ to help reduce liver abscesses in cattle.
HepafleX (virginiamycin) Type A medicated article is approved for the reduction of incidence of liver abscesses in cattle fed in confinement.
Why Do Liver Abscesses Matter?
Liver abscesses cost the US beef industry around $256 million annually with costs attributed to liver and offal condemnation ($72.3 million) and processing speed delays ($11.6 million)1.
Benefits of HepafleX
In a meta-analysis2 of 26 studies consisting of 7,156 animals from 1979 to 2017, virginiamycin reduced the incidence and severity of liver abscesses, resulting in increased weight gain in treated steers and heifers.
At a dose of 19.6 PPM virginiamycin (or 16 g/ton 90% dry matter basis), the study reported:
- 27% reduction in all liver abscesses
- 39% reduction in A+ liver abscesses
Approved with Rumensin®, Rumensin and Experior®, and Rumensin and Optaflexx®
Learn More About Liver Abscesses in Cattle
Sign Up to Learn More About HepafleX
The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions.
HepafleX
Directions for Use: For reduction of incidence of liver abscesses of cattle fed in confinement for slaughter: Feed 85-240 mg/hd/day at 13.5-16.0 g/ton of complete feed (90% dry matter basis).
Important Safety Information:
- Caution: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
- Not for use in animals intended for breeding.
Experior
Caution: Not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals. Do not allow horses or other equines access to feed containing Experior. A decrease in dry matter intake may be noticed in some animals
Indications for use:
For the reduction of ammonia gas emissions per pound of live weight and hot carcass weight in beef steers and heifers fed in confinement for slaughter during the last 14 to 91 days on feed.
Ammonia gas emissions were measured for individual animals or small groups of animals held in environmentally controlled facilities. Based on existing information, reliable predictions of the reduction of ammonia gas emissions cannot be made on a herd, farm, or larger scale. Increased rate of weight gain, improved feed efficiency, and increased carcass leanness have not been demonstrated with this product.
Directions for Use: Feed 1.25 to 4.54 g/ton (1.39 to 5 ppm) of complete feed (90% dry matter basis) to provide 13-90 mg lubabegron/head/day continuously to beef steers and heifers fed in confinement for slaughter as sole ration during the last 14 to 91 days on feed.
Rumensin:
Caution:
Consumption by unapproved species or feeding undiluted may be toxic or fatal. Do not feed to veal calves.
Directions for use:
Growing beef steers and heifers on pasture (stocker, feeder and slaughter) or in a dry lot and replacement beef and dairy heifers:
For increased rate of weight gain: Feed 50 to 200 mg/hd/day in at least 1.0 lb. of Type C Medicated Feed. Or, after the fifth
day, feed 400 mg/hd/day every other day in 2.0 lbs. of Type C Medicated Feed. The Type C Medicated Feed must contain
15 to 400 g/ton of monensin (90% DM basis). Do not self feed.
For the prevention and control of coccidiosis due to Eimeria bovis and Eimeria zuernii: Feed at a rate to provide 0.14 to 0.42 mg/lb. of body weight/day, depending upon the severity of challenge, up to a maximum of 200 mg/hd/day. The Type C Medicated Feed must contain 15 to 400 g/ton of monensin (90% DM basis).
Type C free-choice medicated feeds: All Type C free-choice medicated feeds containing Rumensin must be manufactured according to an FDA-approved formula/specification. When using a formula/specification published in the Code of Federal Regulations (CFR), a Medicated Feed Mill license is not required. Use of Rumensin in a proprietary formula/specification not published in the CFR requires prior FDA approval and a Medicated Feed Mill License.
Tylan
Caution:
Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
Directions for use:
For reduction of incidence of liver abscesses associated with Fusobacterium necrophorum and Arcanobacterium pyogenes: Feed continuously at 8 to 10 g/ton of tylosin (90% DM basis) to provide 60 to 90 mg/hd/d.
Optaflexx
Caution: Not for animals intended for breeding
Directions for use
Complete feed
For increased rate of weight gain and improved feed efficiency: Feed 8.2 to 24.6 g/ton of ractopamine hydrochloride (90% DM basis) continuously in a complete feed to provide 70 to 430 mg/hd/d for the last 28 to 42 days on feed.
For increased rate of weight gain, improved feed efficiency and increased carcass leanness: Feed 9.8 to 24.6 g/ton of ractopamine hydrochloride (90% DM basis) continuously in a complete feed to provide 90 to 430 mg/hd/d for the last 28 to 42 days on feed.
Top dress
For increased rate of weight gain and improved feed efficiency: Feed 70 to 400 mg/hd/d of ractopamine hydrochloride (90% DM basis) continuously in a minimum of 1.0 lb./hd/d top dress Type C medicated feed (maximum 800 g/ton ractopamine hydrochloride) during the last 28 to 42 days on feed.
Experior, HepafleX, Optaflexx, Rumensin, Tylan, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
